Tremelimumab: tested with established drugs
66 studies: they are given beside it. Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingNCT04499053Phase 2Report a problem
- Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver TransplantTerminatedNCT05027425Phase 2Results postedReport a problem
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT04034927Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab for Pediatric MalignanciesActive, not recruitingNCT03837899Phase 1/2Results postedReport a problem
- Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedNCT03753919Phase 2Results postedReport a problem
- Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompletedNCT03702179Phase 2Results postedReport a problem
- CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompletedNCT03638141Phase 2Results postedReport a problem
- Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT03522584Phase 1/2Results postedReport a problem
- Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerCompletedNCT03373760Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03204812Phase 2Results postedReport a problem
- Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerCompletedNCT03132467Early Phase 1Results postedReport a problem
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results postedReport a problem
- Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyCompletedNCT03007407Phase 2Results postedReport a problem
- Brain Irradiation and Tremelimumab in Metastatic Breast CancerCompletedNCT02563925Not applicableResults postedReport a problem
- Study of Tremelimumab in Patients With Advanced Solid TumorsCompletedNCT02527434Phase 2Results postedReport a problem
- CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate CancerTerminatedNCT00702923Phase 1Results postedReport a problem
- Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV MelanomaCompletedNCT00471887Phase 2Results postedReport a problem
- A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results postedReport a problem
- Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive, not recruitingNCT05000710Phase 2Report a problem
- TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingNCT04988945Phase 2Report a problem
- TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 2Report a problem
- Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingNCT04605731Phase 1Report a problem
- Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCCActive, not recruitingNCT04522544Phase 2Report a problem
- Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the TreatmentTerminatedNCT04287894Phase 1Report a problem
- Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic CancerCompletedNCT04156087Phase 2Report a problem
- TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder CancerWithdrawnNCT04073160Phase 1Report a problem
- Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.Status unknownNCT03994393Phase 2Report a problem
- Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2Report a problem
- A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2Report a problem
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2Report a problem
- Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active, not recruitingNCT03704480Phase 2Report a problem
- Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome SequencingCompletedNCT03608865Phase 2Report a problem
- PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell CarcinomaWithdrawnNCT03598816Phase 2Report a problem
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingNCT03482102Phase 2Report a problem
- Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)CompletedNCT03472274Phase 2Report a problem
- Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1Report a problem
- Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCCStatus unknownNCT03450967Phase 2Report a problem
- Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCCCompletedNCT03426657Phase 2Report a problem
- Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal CancerStatus unknownNCT03377400Phase 2Report a problem
- Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)WithdrawnNCT03319316Phase 2Report a problem
- Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasCompletedNCT03283605Phase 1/2Report a problem
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1Report a problem
- Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint InhibitionTerminatedNCT03275597Phase 1Report a problem
- Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for CisplatinTerminatedNCT03234153Phase 2Report a problem
- A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerCompletedNCT03212469Phase 1/2Report a problem
- Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRCCompletedNCT03202758Phase 1/2Report a problem
- Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsActive, not recruitingNCT03158064Phase 2Report a problem
- Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder CancerWithdrawnNCT03150836Phase 2Report a problem
- Synergism of Immunomodulation and Tumor AblationCompletedNCT03101475Phase 2Report a problem
- Pulmonary sarcomatoid_MEDI4736+TremeCompletedNCT03022500Phase 2Report a problem
- Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the LiverCompletedNCT03005002Phase 1Report a problem
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2Report a problem
- Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1Report a problem
- Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer PatientsTerminatedNCT01334099Phase 1Report a problem
- Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal MelanomaCompletedNCT01034787Phase 2Report a problem
- Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT01008358Phase 2Report a problem
- Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder CancerWithdrawnNCT00880854Phase 1Report a problem
- A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced MelanomaTerminatedNCT00585000Phase 1Report a problem
- Safety And Efficacy Study Of CP-675,206 In HIV-Infected PatientsWithdrawnNCT00488995Phase 2Report a problem
- Study to Compare Two Formulations of CP-675,206 Monoclonal AntibodyCompletedNCT00431275Phase 1Report a problem
- Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell CarcinomaCompletedNCT00372853Phase 1Report a problem
- Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After TreatmentCompletedNCT00313794Phase 2Report a problem
- Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00312975Phase 2Report a problem
- CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior TherapyCompletedNCT00257205Phase 3Report a problem
- Study of CP-675,206 in Refractory MelanomaCompletedNCT00254579Phase 2Report a problem
- CP-675,206 In Patients With Advanced MelanomaCompletedNCT00086489Phase 2Report a problem